BACKGROUND: When oseltamivir is administered in extremely high doses (500-1000 mg/kg) to young juvenile rats, central nervous system toxicity and death occurred in some animals. Mortality was not observed in older juvenile rats, suggesting a possible relationship between neurotoxicity and an immature blood-brain barrier. To assess potential neurologic adverse effects of oseltamivir use in infants, a retrospective chart review was performed in infants less than 12 months of age who received oseltamivir, amantadine, or rimantadine. METHODS: The primary objective was to describe the frequency of neurologic adverse events among children less than 12 months of age who received oseltamivir compared with those receiving adamantanes. Medical record databases, emergency department databases, and/or pharmacy records at 15 medical centers were searched to identify patients. RESULTS: Of the 180 infants identified as having received antiviral therapy, 115 (64%) received oseltamivir, 37 (20%) received amantadine, and 28 (16%) received rimantadine. The median dose of oseltamivir was 2.0 mg/kg/dose in 3- to 5-month-old and 2.2 mg/kg/dose in 9- to 12-month-old infants. The maximum dose administered was 7.0 mg/kg/dose. There were no statistically significant differences in the occurrence of adverse neurologic events during therapy among subjects treated with oseltamivir versus those treated with the adamantanes (P = 0.13). CONCLUSIONS: This is the largest report to date of oseltamivir use in children less than 12 months of age. Neurologic events were not more common with use of oseltamivir compared with that of the adamantanes. Dosing of oseltamivir was variable, illustrating the need for pharmacokinetic data in this younger population.
BACKGROUND: When oseltamivir is administered in extremely high doses (500-1000 mg/kg) to young juvenile rats, central nervous system toxicity and death occurred in some animals. Mortality was not observed in older juvenile rats, suggesting a possible relationship between neurotoxicity and an immature blood-brain barrier. To assess potential neurologic adverse effects of oseltamivir use in infants, a retrospective chart review was performed in infants less than 12 months of age who received oseltamivir, amantadine, or rimantadine. METHODS: The primary objective was to describe the frequency of neurologic adverse events among children less than 12 months of age who received oseltamivir compared with those receiving adamantanes. Medical record databases, emergency department databases, and/or pharmacy records at 15 medical centers were searched to identify patients. RESULTS: Of the 180 infants identified as having received antiviral therapy, 115 (64%) received oseltamivir, 37 (20%) received amantadine, and 28 (16%) received rimantadine. The median dose of oseltamivir was 2.0 mg/kg/dose in 3- to 5-month-old and 2.2 mg/kg/dose in 9- to 12-month-old infants. The maximum dose administered was 7.0 mg/kg/dose. There were no statistically significant differences in the occurrence of adverse neurologic events during therapy among subjects treated with oseltamivir versus those treated with the adamantanes (P = 0.13). CONCLUSIONS: This is the largest report to date of oseltamivir use in children less than 12 months of age. Neurologic events were not more common with use of oseltamivir compared with that of the adamantanes. Dosing of oseltamivir was variable, illustrating the need for pharmacokinetic data in this younger population.
Authors: R J Whitley; F G Hayden; K S Reisinger; N Young; R Dutkowski; D Ipe; R G Mills; P Ward Journal: Pediatr Infect Dis J Date: 2001-02 Impact factor: 2.129
Authors: Niranjan Bhat; Jennifer G Wright; Karen R Broder; Erin L Murray; Michael E Greenberg; Maleeka J Glover; Anna M Likos; Drew L Posey; Alexander Klimov; Stephen E Lindstrom; Amanda Balish; Marie-jo Medina; Teresa R Wallis; Jeannette Guarner; Christopher D Paddock; Wun-Ju Shieh; Sherif R Zaki; James J Sejvar; David K Shay; Scott A Harper; Nancy J Cox; Keiji Fukuda; Timothy M Uyeki Journal: N Engl J Med Date: 2005-12-15 Impact factor: 91.245
Authors: Marika K Iwane; Kathryn M Edwards; Peter G Szilagyi; Frances J Walker; Marie R Griffin; Geoffrey A Weinberg; Charmaine Coulen; Katherine A Poehling; Laura P Shone; Sharon Balter; Caroline B Hall; Dean D Erdman; Karen Wooten; Benjamin Schwartz Journal: Pediatrics Date: 2004-06 Impact factor: 7.124
Authors: Megan A O'Brien; Timothy M Uyeki; David K Shay; William W Thompson; Ken Kleinman; Alexander McAdam; Xian-Jie Yu; Richard Platt; Tracy A Lieu Journal: Pediatrics Date: 2004-03 Impact factor: 7.124
Authors: Jairo Gooskens; Marcel Jonges; Eric C J Claas; Adam Meijer; Peterhans J van den Broek; Aloyj M Kroes Journal: JAMA Date: 2009-03-02 Impact factor: 56.272
Authors: Gulam Khandaker; Yvonne Zurynski; Jim Buttery; Helen Marshall; Peter C Richmond; Russell C Dale; Jenny Royle; Michael Gold; Tom Snelling; Bruce Whitehead; Cheryl Jones; Leon Heron; Mary McCaskill; Kristine Macartney; Elizabeth J Elliott; Robert Booy Journal: Neurology Date: 2012-09-19 Impact factor: 9.910
Authors: Laura G Greer; Richard D Leff; Vanessa Laibl Rogers; Scott W Roberts; George H McCracken; George D Wendel; Jeanne S Sheffield Journal: Am J Obstet Gynecol Date: 2011-03-31 Impact factor: 8.661
Authors: Carole Giraud; Sandra Manceau; Mehdi Oualha; Hélène Chappuy; Agnès Mogenet; Patrick Duchêne; Sarah Ducrocq; Philippe Hubert; Jean M Treluyer Journal: Antimicrob Agents Chemother Date: 2010-10-11 Impact factor: 5.191